| Prev Close: | 7.51 |
|---|---|
| Open: | N/A |
| Bid: | 7.60 x 500 |
| Ask: | 7.70 x 600 |
| 1y Target Est: | 8.86 |
| Beta: | -0.86 |
| Next Earnings Date: | 7-Aug-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 6.95 - 13.50 |
| Volume: | 5,005 |
| Avg Vol (3m): | 5,603,020 |
| Market Cap: | 1.64B |
| P/E (ttm): | N/A |
| EPS (ttm): | -0.37 |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- American Medical Association Decision Can Boost Arena, Vivus, And Orexigenat Seeking Alpha(Wed 12:22AM EDT)
- A.M.A. Recognizes Obesity as a Diseaseat New York Times(Tue, Jun 18)
- Consumer Reports Says "Exercise" Rather Than Take This Drugat Motley Fool(Mon, Jun 17)
- What Investors Need To Know About The Efficacy Of Belviqat Seeking Alpha(Mon, Jun 17)
- The Top 5 Diseases Caused by Obesityat Motley Fool(Sun, Jun 16)
- ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VEDGAR Online(Fri, Jun 14)
- BELVIQ® (lorcaserin HCl) CIV Data to be Presented at ENDO 2013PR Newswire(Fri, Jun 14)
- Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare ConferencePR Newswire(Fri, Jun 14)
- Arena Pharmaceuticals: A Trading Vehicle, At Bestat Seeking Alpha(Fri, Jun 14)
- Arena's Belviq Does Not Fare Well With Consumer Reportsat Seeking Alpha(Fri, Jun 14)
- More Reasons Arena Shorts May Have It Dead Wrongat Seeking Alpha(Thu, Jun 13)
- Why The Newest Short Thesis On Arena Is Dead Wrong And Should Be Ignoredat Seeking Alpha(Wed, Jun 12)
- Pricing MannKind Corporation On A Stand-Alone Basisat Seeking Alpha(Wed, Jun 12)
- The Obesity-Drug Wars Officially Beginat Motley Fool(Tue, Jun 11)
- 4 Healthcare Stock Stories For Thursday Inspectionat Wall St. Cheat Sheet(Tue, Jun 11)
Press Releases
- BELVIQ® (lorcaserin HCl) CIV Data to be Presented at ENDO 2013PR Newswire(Fri, Jun 14)
- Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare ConferencePR Newswire(Fri, Jun 14)
- Arena Pharmaceuticals Reports on Launch of BELVIQ® (lorcaserin HCl) CIV for Chronic Weight Management in Adults who are Overweight with a Comorbidity or ObesePR Newswire(Fri, Jun 7)
Reports
- ARNA: Due Diligence Review: Forensic Earnings and ValuationNew Constructs, LLC(Jun 19)
- ValuEngine Industry Report for Medical-biomed/geneticsValuEngine, Inc.(Jun 19)
- ARNA PHARMACEUTICALS INC (ARNA) - REPORT FOR ACTIVE TRADERSPechala's Reports(Jun 17)